

Teva recalls Adrucil injection for potential foreign particle presence

28 July 2015 | Regulatory | By BioSpectrum Bureau

Teva recalls Adrucil injection for potential foreign particle presence



Singapore: Teva Parenteral Medicines has recalled six lots of Adrucil (fluorouracil injection) due to the potential presence of particulate matter identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals.

Adrucil injection is used in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas and is packaged in pharmacy bulk packages.

Administration of an intravenous product with particulate matter has the potential to result in inflammation, allergic reactions, or blockage of blood vessels, leading to tissue death, which may be life-threatening if vital organs are affected.